Vanessa Buatois
Discovery Program Leader Light Chain Bioscience / Novimmune
Vanessa is focused on mAb & bsAbs based therapies with 20-years’ experience in industry. Specialization in discovery and preclinical research for therapeutic Abs in the field of immuno-oncology & inflammation. As a Discovery Program Leader, I led several therapeutic antibody programs from early discovery (e.g. Phage Display) to different stages of development, up to lead candidate selection, with some of them in clinical evaluation.
Seminars
Thursday 9th July 2026
Tumour-Selective Activation of TNFR via Bispecific Antibody Combination
4:10 pm
- Our proprietary k/l bsAb platform allows production of a combination of bsAbs in the same cell and their subsequent purification
- Exploring how bsAbs have been developed to selectively activate TNFR in a tumourassociated antigen (TAA)-dependent manner
- This report investigates whether a combination of bsAbs, pairing TNFR and TAA targeting arms, can further enhance TNFR clustering and activation in the tumour microenvironment
